Scarica l'app Stockscreener
2.48
5.53%
0.13
Dopo l'orario di chiusura:
2.48
Panoramica
Notizia
Cronologia dei prezzi
Financials
Perché PHIO Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$2.35
Aprire:
$2.37
Volume 24 ore:
232.42K
Relative Volume:
0.07
Capitalizzazione di mercato:
$12.24M
Reddito:
-
Utile/perdita netta:
$-11.66M
Rapporto P/E:
-0.3041
EPS:
-8.156
Flusso di cassa netto:
$-11.09M
1 W Prestazione:
+12.22%
1M Prestazione:
+24.00%
6M Prestazione:
+37.78%
1 anno Prestazione:
-58.98%
Intervallo 1D:
$2.3032
$2.53
Intervallo di 1 settimana:
$2.11
$2.53
Portata 52W:
$0.9657
$9.79
Phio Pharmaceuticals Corp Stock (PHIO) Company Profile
Nome
Phio Pharmaceuticals Corp
Settore
Industria
Telefono
(508) 767-3861
Indirizzo
11 APEX DRIVE, SUITE 300A, MARLBOROUGH, MA
Confronta PHIO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PHIO
Phio Pharmaceuticals Corp
|
2.48 | 12.24M | 0 | -11.66M | -11.09M | -8.156 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.16 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
534.91 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.06 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
542.47 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.16 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Phio Pharmaceuticals Corp Stock (PHIO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-05 | Ripresa | H.C. Wainwright | Buy |
| 2020-08-05 | Iniziato | H.C. Wainwright | Buy |
Phio Pharmaceuticals Corp Borsa (PHIO) Ultime notizie
Phio Pharmaceuticals Announces Strategic Initiative and Leadership Changes - TipRanks
Phio Pharmaceuticals Appoints Lisa Carson As Principal Financial OfficerSEC Filing - marketscreener.com
Research Analysts Set Expectations for PHIO FY2025 Earnings - Defense World
What is HC Wainwright’s Forecast for PHIO Q2 Earnings? - Defense World
Phio Pharmaceuticals appoints new strategic and finance VPs By Investing.com - Investing.com South Africa
Phio Pharmaceuticals appoints new strategic and finance VPs - Investing.com India
Phio Pharmaceuticals Announces Strategic Initiative to Create Awareness of the Comprehensive INTASYL siRNA Portfolio - TradingView
Phio Pharmaceuticals Advances 30-Drug Cancer Portfolio as Phase 1b Trial Shows Promise - Stock Titan
Phio Pharmaceuticals (NASDAQ:PHIO) Now Covered by HC Wainwright - Defense World
Phio Pharma (PHIO) Receives Buy Rating and $14 Price Target from HC Wainwright | PHIO Stock News - GuruFocus
H.C. Wainwright assumes coverage on Phio Pharma stock with Buy rating - Investing.com India
Phio Pharmaceuticals (PHIO) Gains 'Buy' Rating with Promising Pr - GuruFocus
2 No-Brainer Artificial Intelligence (AI) Stocks to Buy Right Now - The Globe and Mail
Why BioNTech Stock Soared Today - The Globe and Mail
Best Value Stocks to Buy for May 28th - The Globe and Mail
New Strong Buy Stocks for May 28th - The Globe and Mail
New Strong Buy Stocks For May 28th - Barchart.com
2 ‘Strong Buy’ Small-Cap Stocks With Blockbuster Potential - The Globe and Mail
Phio Pharmaceuticals (NASDAQ:PHIO) Trading 2.8% Higher – Time to Buy? - Defense World
Phio Pharmaceuticals Announces Participation in the Sidoti Micro-Cap Virtual Investor Conference - Newsfile
Phio Reveals Latest Progress on Revolutionary Cancer-Fighting siRNA Technology at Investor Conference - Stock Titan
Phio Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update - Newsfile
Metric Deep Dive: Understanding Phio Pharmaceuticals Corp (PHIO) Through its Ratios - DWinneX
Phio Pharmaceuticals Reports Positive Phase 1b Trial Results - TipRanks
Phio reports positive results in skin cancer trial - Investing.com
Phio reports positive results in skin cancer trial By Investing.com - Investing.com India
Phio Pharmaceuticals Announces Positive Pathology Results in Third Cohort in INTASYL PH-762 Skin Cancer Clinical Trial - Newsfile
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series - Newsfile
Phio Pharmaceuticals (PHIO) to Release Earnings on Thursday - Defense World
Elon Musk Could Bring Nvidia Stock $20 Billion Worth of Good News - The Globe and Mail
Best Value Stocks to Buy for April 23rd - NewsBreak: Local News & Alerts
Analysts Advise You To Maintain Your Position In Phio Pharmaceuticals Corp (NASDAQ: PHIO) - Stocksregister
Best Momentum Stocks to Buy for April 23rd - TradingView
Ratio Revelations: Shuttle Pharmaceuticals Holdings Inc (SHPH)’s Financial Metrics in the Spotlight - DWinneX
Financial Snapshot: Analyzing Phio Pharmaceuticals Corp (PHIO)’s Key Ratio Metrics - DWinneX
Understanding the Risks of Investing in Phio Pharmaceuticals Corp (PHIO) - knoxdaily.com
Phio Pharmaceuticals Corp (PHIO) deserves closer scrutiny - uspostnews.com
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
As Cancer Rates Climb, Wall Street Turns Its Gaze Toward New Frontiers in Cancer Treatments - Baystreet.ca
Contrasting Phio Pharmaceuticals (NASDAQ:PHIO) and RespireRx Pharmaceuticals (OTCMKTS:RSPI) - Defense World
Equities Analysts Offer Predictions for PHIO FY2025 Earnings - Defense World
PHIO Stock Soars as Safety Panel Clears Skin Cancer Drug for Next Dose - MSN
Phio Pharmaceuticals Corp Azioni (PHIO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Phio Pharmaceuticals Corp Azioni (PHIO) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Ferrara Robert L | Director |
Jun 10 '25 |
Buy |
2.42 |
2,500 |
6,050 |
15,666 |
| Bitterman Robert J | Chairman, Pres & CEO |
Jun 09 '25 |
Buy |
2.75 |
1,500 |
4,125 |
25,149 |
| Bitterman Robert J | Chairman, Pres & CEO |
May 21 '25 |
Buy |
1.77 |
3,000 |
5,310 |
22,449 |
| Bitterman Robert J | Chairman, Pres & CEO |
May 22 '25 |
Buy |
1.78 |
1,200 |
2,136 |
23,649 |
| Ferrara Robert L | Director |
May 20 '25 |
Buy |
1.82 |
2,500 |
4,550 |
13,166 |
0.39%
0.42%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):